Latest treating cancer Stories
DOYLESTOWN, Pennsylvania and OXFORD, England, March 31 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, announced today the successful completion of its European launch of CAPHOSOL(R) for the prevention and treatment of oral mucositis associated with cancer therapy, as an adjunct to standard oral care. CAPHOSOL is also indicated for hyposalivation and xerostomia (dryness of the mouth or...
Minimally invasive 'lumpectomy' -- as effective as surgery -- preserves sexual and urinary function; related study shows 3-D mapping biopsy changed patients' management 70 percent of the timeThe so-called "male lumpectomy""”a minimally invasive interventional radiology treatment for prostate cancer"”is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels and particularly those who have failed...
WASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer. However, a new study suggests that some components of green tea may counteract the anticancer effects of one cancer therapy, bortezomib (Velcade(R)), and may be contraindicated for patients taking this medicine to ensure its maximum therapeutic benefit. This study is being...
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Cancer Therapeutics: Market Insight and R&D Pipeline Analysis http://www.reportlinker.com/p096746/Cancer-Therapeutics--Market- Insight-and-RD-Pipeline-Analysis.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) Objectives and Scope The...
SALT LAKE CITY, Oct. 14, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) announced today that a member of its Board of Directors, Dr. Michael Nobel, was the keynote speaker at the Japanese Cancer Symposium recently concluded at the Shizuoka Cancer Center in Shizuoka, Japan. The symposium addressed the theme, "Fulfilling the Promise of Personalized Medicine in Cancer Therapy: Development of the Medical Engineering Platform." The symposium was sponsored by the Frontier...
SCOTTSDALE, Ariz., Sept. 15 /PRNewswire/ -- Carefx Corporation today announced that the nationally recognized Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio, Texas, has gone live after a 90-day implementation with Fusion from Carefx(R), an interoperability platform that aligns patient data across multiple applications to provide a complete view of patient health history. One of only three National Cancer Institute-designated...
By Mankoff, David A Link, Jeanne M; Linden, Hannah M; Sundararajan, Lavanya; Krohn, Kenneth A Tumor receptors play an important role in carcinogenesis and tumor growth and have been some of the earliest targets for tumor- specific therapy, for example, the estrogen receptor in breast cancer. Knowledge of receptor expression is key for therapy directed at tumor receptors and traditionally has been obtained by assay of biopsy material. Tumor receptor imaging offers complementary information...
NEW ORLEANS, June 18, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today presented promising preclinical results on pretargeted therapy of pancreatic cancer that can be further improved when given in small fractions repeatedly, and in combination with gemcitabine. The pretargeted therapy involved TF10, a humanized bispecific antibody that binds to the same...
SAN ANTONIO, July 20 /PRNewswire/ -- The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. CTRC is one of only three sites in the United States, and the only in Texas, enrolling patients. The novel anti-cancer therapy, REOLYSIN(R), is a living virus, not a...
A therapeutic approach for battling cancer that is based on infection with a specially designed virus similar to the one that causes the common cold has shown promise in clinical trials. Now, new research suggests that fever might be a useful weapon in the fight as well. The study, published in the July issue of Cancer Cell, demonstrates that tumor cells are even more sensitive to viral therapy after they have been incubated at an elevated temperature. The findings could have a significant...
